Health Cluster Sector - Luís Soares

1 1

HEALTH SECTOR overview, trends and opportunities

BETA-TRENDS SEA & LIFE SCIENCES CLUSTERS

05 September 2012

The global Health market(s)

Total health expenditure: US$ 6.5 x1012 ::

Pharmaceutical market: US$ 850 x109 ::

Medical device market: US$ 300 x109 ::

Total expenditure on health as % of GDP (2010)

Source: WHO

Creating value: the Health industries

Produtos

Farmacêuticos

Dispositivos médicos

e consumíveis

Indústria

I&D, TIC

UTENTE

Cuidados de

saúde

Comércio por grosso

Farmácias

Distribuição/Comércio

Prestação de cuidados

Elementos auxiliares de diagnósticoServiços às

empresas (consultoria)

Indústria

Química

Papel, Edição, Impressão

PlásticoVidro

Metalúrgia Indústria Electrónica

I&D, TIC

Source: ISEG

The Health value chain ::

Is Portugal a competitive player?

The R&D investment has been growing consistently ::


# Company / Group R&D Expenditure (€)

6 Bial – Portela & Cia, SA 43,013,339

16 Alert – Life Sciences Computing, SA 12,041,623

30 Hovione FarmaCiencia, SA 6,167,050

33 Tecnimede – Sociedade Técnico-Medicinal, SA 5,754,878

52 Biocant – Associação de Transferência de Tecnologia 3,133,354

55 Eurotrials – Consultores Científicos, SA 2,927,239

61 Ablynx, SA 2,610,585

62 Bluepharma – Indústria Farmacêutica, SA 2,544,467

94 Grupo Azevedos 1,713,365

98 Grupo AtralCipan 1,663,999

100 Lilly Portugal – Produtos Farmacêuticos, Lda 1,646,827

# Hospital / Group of HospitalsR&D Expenditure

(€)

1 Centro Hospitalar do Porto, EPE 5,449,273

2 Centro Hospitalar de Lisboa Central, EPE 4,036,972

3 Centro Hospitalar de Lisboa Norte, EPE 3,385,751

4 Hospital de São João, EPE 2,761,268

5 Hospitais da Universidade de Coimbra, EPE 2,635,503

6 Centro Hospitalar de Lisboa Ocidental, EPE 2,300,726

7 Grupo José de Mello Saúde, SGPS, SA 1,219,110

8 Instituto Português de Oncologia do Lisboa Francisco Gentil, EPE 1,068,554

9 Instituto Português de Oncologia do Coimbra Francisco Gentil, EPE 1,036,725

10 Instituto Português de Oncologia do Porto Francisco Gentil, EPE 954,018 ~25 M€

~83 M€ Company / Group

Researchers

(FTE)

PhDs

(FTE)

Ablynx, SA 22.8 9.8 (#5)

Alert – Life Sciences Computing, SA 210.4 10.2 (#4)

Bial – Portela & Cia, SA 53.5 14.1 (#2)

Biocant – Associação de Transferência de Tecnologia 31.2 10.8 (#3)

Bluepharma – Indústria Farmacêutica, SA 34.1 1.0

Critical Health, SA 14.8 1.0

Eurotrials – Consultores Científicos, SA 68.0 2.0

Grupo AtralCipan 14.3 1.4

Grupo Azevedos 10.2 n.a.

Hovione FarmaCiencia, SA 83.0 22.0 (#1)

Tecnimede – Sociedade Técnico-Medicinal, SA 49.5 1.0

Source: GPEARI/MCTES

Number of researchers and PhDs in selected Health sector companies (2009)

Portugal has a growing number of highly-qualified people ... ::

Higher education: Students enrolled and graduates

Source: GPEARI / MCTES

Graduates Enrolled

(2006-2007) (2007-2008)

Biology and Biochemistry 1,819 9,696

Dental sciences 637 3,522

Pharmaceutical sciences 893 6,896

Nursing 5,912 19,774

Medicine 1,434 9,053

Public health services 253 603

Diagnostic and therapeutic

technologies3,001 7,468

Therapy and rehabilitation 2,132 6,976

Engineering: biomedical, clinical,

pharmaceutical, health304 1,525

Health (not included in other areas) 8 169

Total 16,393 65,682

Education area


... including PhDs ... ::

PhDs in Life, Medical and Health Sciences


0

20

40

60

80

100

120

140

160

180

200

No

. o

f P

hD

s

Years

Life Sciences Medical and Health Sciences


... and the value chain now employs more researchers and PhDs. ::


Company / GroupResearchers

(FTE)

PhDs

(FTE)

Ablynx, SA 22.8 9.8 (#5)

Alert – Life Sciences Computing, SA 210.4 10.2 (#4)

Bial – Portela & Cia, SA 53.5 14.1 (#2)

Biocant – Associação de Transferência de Tecnologia 31.2 10.8 (#3)

Bluepharma – Indústria Farmacêutica, SA 34.1 1.0

Critical Health, SA 14.8 1.0

Eurotrials – Consultores Científicos, SA 68.0 2.0

Grupo AtralCipan 14.3 1.4

Grupo Azevedos 10.2 n.a.

Hovione FarmaCiencia, SA 83.0 22.0 (#1)

Tecnimede – Sociedade Técnico-Medicinal, SA 49.5 1.0

Source: GPEARI/MCTES

Number of researchers and PhDs in selected

Health sector companies (2009)

The scientific production has been increasing sharply ... ::


Scientific production: Life, Medical and Health Sciences


0

500

1000

1500

2000

2500

3000

3500

No

. o

f p

ub

lic

ati

on

s

Years

Life Sciences Medical and Health Sciences


11 11

From knowledge

to market

129 Members

Hospitals

Pharma & Biotech

2000 PhDs

8500 physicians

8000 beds

1250 M€ turnover

80 M€ in R&D

4000 employees

570 M€ turnover

30 M€ in R&D

6000 employee

R&D Institutions + Universities

3100 researchers in Health

17 M€ in R&D

130 PhDs

30 PhDs

Medical Devices & Services

Key figures

To become a Member, please visit www.healthportugal.com

To turn Portugal into a competitive player in the

research, design, development, manufacturing

and commercialization of health-related products

and services,

in selected market and technological niches, targeting

the most demanding and relevant international markets,

based on the recognition of its excellence,

technological level and competences in the field of

innovation.

Mission

Strategic vision

Knowledge / R&D + I . diseases

. pharmaceutical . medical devices

. biotechnology . nanotechnology

Enterprise dynamics . healthcare

. pharmaceutical . biotechnology

. auxiliary diagnostic means . medical devices

Management . ICTs

. process automation . productivity

Public support / Demonstration actions . support to investment and innovation . public procurement . FDI attraction . training . idea contests . pilot projects

+ social and economical development

+ business + exports + employment (qualified) + health

STRATEGIC OPTIONS

well-being / ageing

diseases (neurodegenerative, cancer,

cardiovascular, osteoarticular degenerative,

inflammatory, infectious and metabolic)

e-health (AAL-Ambient Assisted Living,

process integration and automation)

Objectives

> to change the current

knowledge-exploitation

paradigms

> generalization of translational

research and clinical research

> bioengineering ecosystems

> to improve the cooperation/

coopetition environment

> international recognition

> strengthen the company

base and the R&D system

in 3-5 years

5 new drugs

50 new diagnostic

methods/ devices/

services

4 000 million € turnover

(>70% exports)

in 10 years

Horizontal Anchor Projects (promoted by HCP)

Translational Research ::

Research “from bench to bedside and back again”...

Intellectual Property and Technology Transfer ::

Protection and exploitation of new knowledge and technologies...

International Promotion & Networking ::

Promoting Portugal globally as a competitive player in Health...

Promoting and fostering cooperation amongst players...

... to turn knowledge into health and wealth

Flagship Projects (co-promoted by HCP members)

AAL4ALL – Ambient Assisted Living for All ::

Mobilization of an industrial ecosystem for the massification of products

and services in the area of Ambient Assisted Living (AAL), focused on

the definition of specifics standards (for products and services).

Investment: 8.2 M€ (QREN 5.0 M€)

Flagship Projects (co-promoted by HCP members)

Do IT – Development and Operation of Translational Research ::

Development of translational research strategies and organizational

models applicable to the entities of the Portuguese health value chain

(companies, R&D institutions and hospitals).

Development of innovative and competitive products and services for

the global Health market.

Investment: 8.6 M€ (QREN 5.0 M€)

Some trends and opportunities ahead

in the Health sector


A changing landscape: different needs, different demands... ::

▪ Increased longevity and ageing

populations.

▪ New epidemiologic patterns:

. Changes in the main causes of death.

. Chronic diseases.

. Emerging/re-emerging infectious diseases.

. Pandemics.

▪ Increased purchasing power (namely in

highly-populated countries with emerging

economies).

▪ Citizens/users more informed, more

demanding and with higher (geographic)

mobility.

▪ … Source: WHO

▪ Cost containment.


... new opportunities! ::

[image]

[image]

[image]


... new opportunities! ::

[image]


Changing paradigms in healthcare delivery: P4 Medicine ::

▪ Predictive

▪ Preventive

▪ Personalized

▪ Participatory

[image]


Sectors /

Market

areas

Resources / Technology Platforms | Typologies of products, processes and services

Biotechnology

& Omics ICT & Electronics Nanotechnology

Endogenous /

Natural resources

Organization /

Management

Pharma

▪ Targeted therapies

▪ Biopharmaceuticals

▪ New antibiotics

▪ Drugs for neglected

diseases

▪ Biomarkers

▪ Vaccines

▪ Bioinformatics tools ▪ In-situ drug delivery

systems

▪ Natural compounds

(sea, plants, ...)

▪ Citizen

empowerment

▪ P4 medicine

▪ New business

models

▪ New financing

models

▪ Open innovation

Medtech &

Diagnostics

▪ Regenerative

medicine

▪ Companion

diagnostics

▪ Ambient Assisted

Living products

▪ Point-of-care

products

▪ Biomedical and

biological imaging

▪ Nanobots

▪ Biomedical and

molecular imaging

▪ Minimally invasive

surgery

▪ Nanoimplants

Healthcare &

Wellbeing

delivery

▪ AAL services

▪ e-Health /

telemedicine

▪ Computer aided

diagnostics

▪ Health/medical

tourism

Typologies of products, processes and services: a few examples. ::

26

www.healthportugal.com

www.scienceportugal.com

26

Rua Eng.º Frederico Ulrich, 2650 Moreira da Maia

4470-605 Maia PORTUGAL

Tel: (+351) 220 968 183

[email protected]

www.healthportugal.com

Luís Soares [email protected]

Health & Medicine

Health Cluster Sector - Luís Soares